The Technical Analyst
iTeos Therapeutics, Inc. [ITOS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
iTeos Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.60% $10.86
America/New_York / 23 apr 2024 @ 11:41
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 389.08 mill |
| EPS: | -3.15 |
| P/E: | -3.45 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 35.84 mill |
| Avg Daily Volume: | 0.279 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.45 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.59x |
| Company: PE -3.45 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$7.13 (-34.31%) $-3.72 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 10.21 - 11.50 ( +/- 5.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-07 | Gall Matthew | Buy | 163 200 | Stock Option (Right to Buy) |
| 2024-03-07 | Call Matthew | Buy | 225 000 | Stock Option (Right to Buy) |
| 2024-03-07 | Mcgrath Yvonne | Buy | 153 600 | Stock Option (Right to Buy) |
| 2024-03-07 | Detheux Michel | Buy | 590 400 | Stock Option (Right to Buy) |
| 2024-03-07 | Desimone Jill | Buy | 44 766 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 63.70 |
| Last 98 transactions |
| Buy: 4 056 310 | Sell: 3 240 538 |
Forecast:
13:21 - $11.02
Live Trading Signals (every 1 min)
Forecast
1: 11:51 - $10.85
Forecast 2: 12:41 - $10.92
Forecast 3: 13:21 - $11.02
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.86 (0.60% ) |
| Volume | 0.0525 mill |
| Avg. Vol. | 0.279 mill |
| % of Avg. Vol | 18.78 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ITOS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $10.57 | N/A | Active |
|---|
ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Latest Press Releases
2024-04-07 16:30:00 - Press Release
Iteos Presents Eos-984 Preclinical Data Demonstrating Restoration Of T Cell Activity From Adenosine Suppression At The American Association For Cancer Research Annual Meeting 2024
Watertown, mass. and gosselies, belgium, april 07, 2024 (globe newswire) -- iteos therapeutics, inc. (nasdaq: itos), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on eos-984, a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ent1) in oncology, at the american association for cancer research (aacr) annual meeting, being held april 5-10, 2024 in san diego, california.
2024-03-06 07:01:00 - Press Release
Iteos Appoints Oncology Veteran Jill Desimone To Its Board Of Directors
Watertown, mass. and gosselies, belgium, march 06, 2024 (globe newswire) -- iteos therapeutics, inc. (nasdaq: itos), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of jill desimone to its board of directors, effective march 7, 2024, where she will serve on the company's audit committee.
2024-03-06 07:00:00 - Press Release
Iteos Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Updates
- multiple clinical milestones across portfolio anticipated in 2024, including two phase 2 trials assessing belrestotug + dostarlimab in 1l nsclc and 1l hnscc - completed enrollment of third dose cohort in phase 1 trial of eos-984 - preclinical presentations on role of ent1 at sitc spring scientific and profile of eos-984 at aacr annual meeting - cash and investment balance of $632.7 million as of december 31, 2023 expected to provide runway through 2026 across a number of impactful portfolio milestones - oncology veterans jill desimone and david k. lee to join board of directors
2024-03-05 16:30:00 - Press Release
Iteos To Highlight Preclinical Data On First-in-class Eos-984 Targeting Ent1 At The American Association For Cancer Research Annual Meeting 2024
Watertown, mass. and gosselies, belgium, march 05, 2024 (globe newswire) -- iteos therapeutics, inc. (nasdaq: itos), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on eos-984, a first-in-class small molecule antagonist targeting equilibrative nucleoside transporter 1 (ent1), at the american association for cancer research (aacr) annual meeting, being held april 5-10, 2024 in san diego, california.
2024-03-01 07:00:00 - Press Release
Iteos To Participate In Upcoming Investor Conferences
Watertown, mass. and gosselies, belgium, march 01, 2024 (globe newswire) -- iteos therapeutics, inc. (nasdaq: itos), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in march:
Latest News
2024-03-01 07:00:00 - GlobeNewsWire
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in March:
2024-02-26 07:16:04 - Zacks Investment Research
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-01-10 08:01:12 - Seeking Alpha
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
2023-11-27 11:17:24 - Zacks Investment Research
Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 283.6% in iTeos Therapeutics, Inc. (ITOS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-11-13 11:18:11 - Zacks Investment Research
Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher
iTeos Therapeutics, Inc. (ITOS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2023-11-04 09:00:00 - Seeking Alpha
iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail
iTeos Therapeutics is a clinical-stage biotech focused on developing immunotherapies for solid tumors, with a focus on non-small cell lung cancer (NSCLC). Their most advanced project is belrestotug, an antibody targeting the TIGIT immune checkpoint, being co-developed with GlaxoSmithKline. The company has a strong financial position with $216 million in cash and investments, providing them with the funds to see the fruits of their clinical trials.
2023-10-16 06:01:07 - Zacks Investment Research
iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
2023-09-06 07:00:00 - GlobeNewsWire
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 06, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September:
2023-08-25 15:55:37 - Seeking Alpha
iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall
iTeos Therapeutics focuses on developing immuno-oncology treatments for cancer patients, with a focus on TIGIT-targeted therapies. Roche's accidental disclosure of positive data on its anti-TIGIT therapy led to a surge in iTeos' stock value. iTeos has a strong financial position with $677.5M in liquid assets and a negative enterprise value, making it an attractive investment opportunity.
2023-06-04 10:04:13 - Seeking Alpha
iTeos Therapeutics: Trading Under Cash Value
Today, we circle back on small oncology concern iTeos Therapeutics, Inc. for the first time since last July. The company is advancing its two primary compounds in its pipeline and has a potentially lucrative partnership with GlaxoSmithKline. The stock also trades under the net cash on iTeos' balance sheet. An updated investment analysis follows in the paragraphs below.